Journal of Medicinal Chemistry · 2008 · 32 citations · 9 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationAntiviral AgentsAntiviral PharmacologyLead Compound DesignLigand BindingLigand-based DesignPotency OptimizationAffinity LigandsAntiviral Drug DesignAntiviral Structure-activity RelationshipsAntiviral TherapeuticsChemokine Receptor PharmacologyPiperidine ChemistryReceptor Binding OptimizationSmall-molecule Library Design
We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the (125)I-[MIP-1beta] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC 50 = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC 50 = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.
9
Novel software tools for chemical diversity
Robert S. Pearlman · Perspectives in Drug Discovery and Design · 1998 · 177 citations · Full text
Jayaram R. Tagat, Stuart W. McCombie, Dennis V. Nazareno et al. · Journal of Medicinal Chemistry · 2004 · 136 citations · Full text